距综合癌症中心距离对胶质母细胞瘤治疗的影响
该单中心回顾性研究纳入2018至2022年在该国家癌症研究所指定综合癌症中心(CCC)接受治疗的167例新诊断IDH野生型胶质母细胞瘤患者,分析居住距离与总生存(OS)及临床试验入组的关系。多变量分析显示中等距离组OS显著差于近距离组(HR 1.61,95%CI 1.03–2.50,p=0.035),且距离越远临床试验入组率越低(近43%、中35%、远18%;p=0.0001)。
要点
- 中等距离组患者OS较多变量校正后仍显著劣于近距离组。
- 距离越远临床试验入组率越低,远距离组仅18%。
- 改善专科诊疗可及性与试验参与或有助于减少结局差异。
核心结论
- 距综合癌症中心的距离与IDH野生型胶质母细胞瘤患者的总生存及临床试验可及性差异相关。
- 鉴于临床试验是GBM的标准治疗选项之一,需要改善专科诊疗与试验参与的可及性以减少结局差异。
研究设计与样本
- 单中心回顾性研究,纳入2018至2022年在该国家癌症研究所指定综合癌症中心接受治疗的新诊断IDH野生型GBM患者(2021年WHO分类),共167例。
- 距离按分类变量与连续变量分析,采用单变量和多变量Cox回归模型并校正已知预后因素。
主要发现
- 各距离组基线特征相似。
- 单变量分析中,近距离组与中等距离、远距离组之间OS无显著差异。
- 多变量分析中,中等距离组OS显著差于近距离组(HR 1.61,95%CI 1.03–2.50,p=0.035)。
- 距离增加与临床试验入组率显著降低相关(近43%、中35%、远18%;p=0.0001)。
关键数值与推荐
- 多变量Cox回归:中等距离组对比近距离组OS的HR 1.61(95%CI 1.03–2.50,p=0.035)。
- 临床试验入组率:近距离43%、中等距离35%、远距离18%(p=0.0001)。
临床怎么用
- 对居住地距离综合癌症中心较远的GBM患者,应关注其临床试验可及性并主动提供入组信息与转诊支持。
- 可将距离因素纳入随访与支持策略,以减少诊疗可及性带来的结局差异。
局限性
- 为单中心回顾性研究,样本来自单一综合癌症中心,结果外推需谨慎。
- 原文未报告距离的具体划分界值及更多局限性的细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Glioblastoma (GBM) is an aggressive primary brain tumor with poor overall survival. Patients living in rural areas have worse outcomes than those in metropolitan regions, but the effect of distance from subspecialty care on survival and clinical trial participation remains unclear. We evaluated the association between distance to a National Cancer Institute-designated Comprehensive Cancer Center (CCC) and overall survival (OS) and clinical trial enrollment in patients with isocitrate dehydrogenase wild-type GBM. METHODS: We retrospectively identified patients with newly diagnosed isocitrate dehydrogenase wild-type GBM (2021 World Health Organization classification) who received treatment at our CCC (2018-2022). Distance from the CCC was analyzed as both categorical and continuous variables. Univariable and multivariable Cox regression models were performed, adjusting for established prognostic factors. RESULTS: The 167 patients had similar baseline characteristics across distance groups. In univariable analyses, no significant difference in OS was observed between patients living near the CCC and those at intermediate or far distances. In multivariable analysis, patients in the intermediate-distance group demonstrated significantly worse OS compared with the near group (hazard ratio 1.61, 95% confidence interval 1.03, 2.50, p = 0.035). Increasing distance was associated with significantly lower clinical trial enrollment (near 43%, intermediate 35%, and far 18%; p = 0.0001). CONCLUSIONS: Distance from a CCC was associated with disparities in survival and access to clinical trials among patients with isocitrate dehydrogenase wild-type GBM. Given that clinical trials represent a standard-of-care option for GBM, strategies to improve access to subspecialty care and trial participation are needed to reduce outcome disparities.
引用
- Mohl S, Tenhoeve SA, King S, et al. The impact of distance in treating glioblastoma: a retrospective single-center study. J Neurooncol. 2026. PMID: 42105122. doi:10.1007/s11060-026-05596-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。